Results Of VYVANSE(TM) (lisdexamfetamine Dimesylate) Pivotal Trial In Adult ADHD Presented At Major Scientific Meeting

Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once- daily VYVANSE(TM) (lisdexamfetamine dimesylate), the first prodrug stimulant. [click link for full article]

More: continued here

Filed under: ADHD on October 26th, 2007